Bayer has begun conversations with the legal representation of its workers in Spain to initiate an Employment Regulation File (ERE) that will affect 135 positions in its pharmaceutical division, as reported by the company in a statement, according to Europa Press.
This measure, which will affect almost 6% of the total workforce in Spain made up of more than 2,400 professionals, “is a consequence of the market situation in the country, marked by the difficulties of access to new drugs, and the maturity of some of the company’s key brands”, declared the multinational.
Given this context, Bayer has decided to focus its trade promotion action on new launches with growth potential, thus reducing efforts on products that are in the final phase of their life cycle.
Likewise, the company seeks to adjust its structures and modify the organizational model of commercial promotion and support of various business units.
This will allow the pharmaceutical company to “continue advancing towards a highly innovative and competitive organization that responds quickly and effectively to the needs of patients and customers”, as it has indicated in a press release.
In addition, Bayer has ensured that it maintains its commitment to all agents in the health ecosystem to continue improving the quality of life of patients and contributing to the sustainability of the health system.
The company also wanted to emphasize that it will carry out this process “in a socially responsible manner and will inform, within the legal framework, transparently and regularly on any progress.”
Bayer has informed the Government of the Principality of Asturias that the announcement to apply an employment regulation file (ERE) that affects 13 people at the Lada plant in Asturias does not put the future or the investments announced by the company at risk.
According to the information provided by the pharmaceutical company to the Ministry of Ecological Transition, Industry and Economic Development of the Principality, these measures “are of a temporary nature and derive from incidents in the Spanish market for pharmaceutical products.”
The multinational currently produces four active ingredients in Asturias, including acetylsalicylic acid, which serves as the basis for the manufacture of aspirin.
Bayer, which has more than 140 workers in the region, has informed the Government of Asturias that this decision does not compromise the investments announced in its center in the autonomous community.
For its part, the Government of the Principality trusts “that the period of negotiation of the file with the representation of the workers will allow us to find the best solutions for the people affected.”
